BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $5.19, for a total transaction of $41,520.00. Following the transaction, the director now owns 606,254 shares in the company, valued at $3,146,458.26. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
BDSI stock opened at $4.84 on Friday. BioDelivery Sciences International, Inc. has a twelve month low of $1.70 and a twelve month high of $5.37. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82. The company has a market cap of $342.69 million, a PE ratio of -6.63 and a beta of 0.46.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. The business had revenue of $18.03 million during the quarter, compared to the consensus estimate of $16.15 million. On average, analysts anticipate that BioDelivery Sciences International, Inc. will post -0.24 EPS for the current year.
Several research analysts recently commented on BDSI shares. Janney Montgomery Scott restated a “buy” rating and issued a $5.00 price target on shares of BioDelivery Sciences International in a report on Thursday, January 31st. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 11th. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Friday, January 25th. BidaskClub raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, January 11th. Finally, SunTrust Banks began coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They issued a “buy” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. BioDelivery Sciences International has a consensus rating of “Buy” and an average price target of $5.79.
ILLEGAL ACTIVITY WARNING: “BioDelivery Sciences International, Inc. (BDSI) Director Francis E. Odonnell, Jr. Sells 8,000 Shares” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/biodelivery-sciences-international-inc-bdsi-director-francis-e-odonnell-jr-sells-8000-shares.html.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.